Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Preparing word cloud

×

Search

Type in a keyword to search

Filter by last modified time
See new records

Current Facets and Filters

  • Availability:2016. (facet)
  • Keywords:cancer (facet)
  • Website Status : Ascending

Facets

Sort alphabetically | Sort by count

Recent searches

SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.

(last updated: Oct 12, 2019)

Physical Resource or Software Tool Software

9 Results - per page

Resource NameResource TypeDescriptionKeywordsResource IDProper CitationParent OrganizationRelated ConditionFunding AgencyRelationReferenceWebsite StatusAlternate IDsAlternate URLsOld URLs
The Biomedical Research Foundation - Current ResearchResource, topical portal, portal, data or information resourceTHIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. This laboratory facilities contain core research space for monoclonal antibody production, oligonucleotide and peptide synthesis, gene cloning, DNA sequencing, high performance liquid chromatography, tissue culture, positron emission tomography, magnetic resonance spectroscopy and electron microscopy.drug, electron microscopy, - flow cytometry, gene, abuse, alcohol, automated cell imaging, cancer, cloning, confocal and digital microscopy, dna, dna gene chip analysis, immunology, inflammation, ischemic disorder, liquid chromatography, magnetic resonance spectroscopy, mass spectrometry, monoclonal antibody production, neuroscience, oligonucleotide, peptide, polymerase chain reaction (pcr), positron emission tomography, sequencing, signal transduction, synthesis, tissue cultureSCR_001564(The Biomedical Research Foundation - Current Research, RRID:SCR_001564)Last checked downnif-0000-10446http://www.biomed.org/homehttp://www.biomed.org/bio_med_research.cfm
MD Anderson Pancreas Tissue BankResource, biomaterial supply resource, data or information resource, material resource, tissue bank, databaseTHIS RESOURCE IS NO LONGER IN SERVCE, documented September 2, 2016. A clinical database and PTB were created in 1990 and 2000, respectively, to collect clinical information and biospecimens from patients with suspected or confirmed pancreatic cancer, other pancreatic diseases, and tumors of the duodenum, ampulla of Vater, and distal bile duct. Standard procedures for biospecimen collection and data entry were developed. The use of human tissue for research is an invaluable tool to understand the basic mechanisms of tumor biology, which will hopefully lead to the development of new therapeutic approaches to pancreatic cancer treatment. The cornerstone of any large translational research program is the development of an accurate and comprehensive tumor bank. All tumors removed in the operating room are sampled for careful pathologic study and the remainder of the tumor is promptly stored in our Pancreas Tissue Bank (PTB) to be used for research. Other samples, including blood, pancreatic juice and biopsy material, can also be utilized to identify early markers for pancreatic cancer. The molecular profile of tumors in the PTB can be linked to information in our clinical database to provide insight on the relationship between molecular events and clinical outcome. Patients may contribute to the tissue banking effort by choosing to participate in select research protocols. Protecting patient privacy is of great importance and thus, to maintain the confidentiality of health information, the PTB complies with all federal and institutional regulations governing research with human participants.clinical, tumor, cancer, bodily fluid, tissue, tumor, blood, pancreatic juice, biopsy material, pancreatic cancer, pancreatic disease, tumor of the duodenum, tumor of the ampulla of vater, tumor of the distal bile ductSCR_004983(MD Anderson Pancreas Tissue Bank, RRID:SCR_004983)University of Texas MD Anderson Cancer Center Pancreatic cancer, Pancreatic disease, Tumor of the duodenum, Tumor of the ampulla of Vater, Tumor of the distal bile ductlisted by: One Mind Biospecimen Bank ListingPMID:18256882Last checked downnlx_94016http://www.mdanderson.org/education-and-research/research-at-md-anderson/basic-science/research-programs/pancreatic-cancer-research/from-bench-to-bedside/human-tumor-bank-database-expansion.html
University of Texas Tumor BankResource, biomaterial supply resource, material resource, tissue bankTHIS RESOURCE IS NO LONGER IN SERVCE, documented September 2, 2016.tissue, tumor tissue, dna, rna, frozen, paraffin, fresh, cancer, tumorSCR_005048(University of Texas Tumor Bank, RRID:SCR_005048)University of Texas Medical Branch at Galveston Cancer, Tumorlisted by: One Mind Biospecimen Bank ListingLast checked downnlx_99346
Adenoma Polyp Tissue BankResource, biomaterial supply resource, material resourceTHIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. The Adenoma Polyp Tissue Bank (APTB) receives whole blood from patients enrolled in the Prevention of Sporadic Colorectal Adenomas with Celecoxib clinical trial. We have reached our accrual on blood submissions, so we will no longer be receiving blood specimens The objectives of this trial are as follows: A. To determine the efficacy and safety of celecoxib versus placebo in preventing the occurrence of newly detected colorectal adenomas in subjects at increased risk for colorectal carcinoma. In addition to incidence, other established risk factors will be evaluated for their association with occurrence of new colorectal adenomas, including cancer family history and adenoma size, histopathologic grade, multiplicity and location. Primary assessment of treatment efficacy will be the reduction in the number of subjects with adenomas at colonoscopy after Year 1 and Year 3 of study drug use. Secondary assessments of treatment efficacy will be 1) the number of adenomas 2) the histopathologic grade of adenomas and 3) the size of adenomas, also measured after one year and three years of study drug use. These factors will be incorporated into a risk model for predicting adenoma occurrence and response to celecoxib. B. To determine the efficacy of celecoxib versus placebo in modulating one or more of a panel of biomarkers for colorectal cancer at the cellular and molecular level sampled in a subset of subjects at selective sites at baseline and after Year 1 and Year 3 of study drug use. These biomarkers will include measurements of aberrant crypt foci (ACF), proliferation (index and crypt distribution), apoptosis (index and crypt distribution), COX expression and activity. If modulation of one or more mucosal biomarkers occur, we will explore whether it correlates with the development of incident colorectal neoplasia (adenomas/carcinomas), thereby attempting to validate the surrogacy of that biomarker. C. To develop a specimen bank. Serum and white blood cells are isolated from whole blood and adenoma tissue blocks and slides are banked. Banked specimens will become available for use in correlative science studies at a later point. This project began in 1999 and will be extended through 2006. The lead principal investigator is Monica M. Bertagnolli, MD, Brigham and Women''s Hospital, Boston, MA, and the APTB Director is Scott Jewell, Ph.D., Department of Pathology, The Ohio State University. The APTB is supported by the NIH, NCI Division of Cancer Prevention, in connection with the Strang Cancer Prevention Center, Cornell University, New York.blood, serum, white blood cell, adenoma tissue, tissue, whole blood, block, slide, colorectal adenoma, celecoxib, adenoma, cancer, colorectal cancer, clinical trial, polyp, risk factorSCR_005366(Adenoma Polyp Tissue Bank, RRID:SCR_005366)Human Tissue Resource Network Increased risk for colorectal carcinomaNCIlisted by: One Mind Biospecimen Bank ListingLast checked downnlx_144435
LIBRO-1: Individualized prediction and prevention of breast cancerResource, disease-related portal, topical portal, research forum portal, biomaterial supply resource, portal, material resource, data or information resourceTHIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. Libro-1 is a study with the overall aim to identify prognostic factors for breast cancer. The study comprise women in the Stockholm-Gotland region that were diagnosed with breast cancer between the years 2001-2008. Register data (tumor characteristics and treatment), lifestyle factors and blood samples have been collected from the participants.breast, cancer, tumor, treatment, woman, female, lifestyle, prognostic factor, prediction, preventionSCR_006036(LIBRO-1: Individualized prediction and prevention of breast cancer, RRID:SCR_006036)Karolisnka Biobank Breast cancerlisted by: One Mind Biospecimen Bank ListingLast checked downnlx_151436
CDKN2A DatabaseResource, data or information resource, databaseTHIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. The CDKN2A Database presents the germline and somatic variants of the CDKN2A tumor suppressor gene recorded in human disease through June 2003, annotated with evolutionary, structural, and functional information, in a format that allows the user to either download it or manipulate it for their purposes online. The goal is to provide a database that can be used as a resource by researchers and geneticists and that aids in the interpretation of CDKN2A missense variants. Most online mutation databases present flat files that cannot be manipulated, are often incomplete, and have varying degrees of annotation that may or may not help to interpret the data. They hope to use CDKN2A as a prototype for integrating computational and laboratory data to help interpret variants in other cancer-related genes and other single nucleotide polymorphisms (SNPs) found throughout the genome. Another goal of the lab is to interpret the functional and disease significance of missense variants in cancer susceptibility genes. Eventually, these results will be relevant to the interpretation of single nucleotide polymorphisms (SNPs) in general. The CDKN2A locus is a valuable model for assessing relationships among variation, structure, function, and disease because: Variants of this gene are associated with hereditary cancer: Familial Melanoma (and related syndromes); somatic alterations play a role in carcinogenesis; allelic variants occur whose functional consequences are unknown; reliable functional assays exist; and crystal structure is known. All variants in the database are recorded according to the nomenclature guidelines as outlined by the Human Genome Variation Society. This database is currently designed for research purposes only and is not yet recommended as a clinical resource. Many of the mutations reported here have not been tested for disease association and may represent normal, non-disease causing polymorphisms.evolutionary, familial, function, functional, gene, gene-, genetic, allele, allelic, alteration, cancer, carcinogenesis, cdkn2a, crystal, disease, genome, germline, hereditary, human, locus, melanoma, missense, model, mutation, nucleotide, or disease- specific databases, polymorphism, single, snp, somatic, structural, structure, suppressor, syndrome, system-, tumor, variant, variationSCR_008179(CDKN2A Database, RRID:SCR_008179)University of Vermont; Vermont; USA Last checked downnif-0000-21079
Spanish National Tumour Bank NetworkResource, topical portal, database, biomaterial supply resource, tissue bank, portal, material resource, data or information resourceTHIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. The need to use human neoplastic tissue under ideal conditions is currently of particular importance due to the development molecular pathology techniques that allow large-scale studies of genetic expression that are also of clinical significance. The Tumour Bank Network (TBN), instigated and coordinated by the Molecular Pathology Programme (MMP) aims to respond to this need by the promoting of Tumour Banks in Spanish hospitals. This will be achieved through the application of homogeneous procedures for the collection, processing and storage of neoplastic and normal tissue samples in such a way as to make molecular studies possible, avoiding that avoid the intrinsic bias of multi-centre studies possible. These Hospital Tumour Banks are based within the Pathology Departments of the collaborating Hospitals, that are interconnected through a computer-based network. In this way, each Centre''s tissue remains in the Hospital itself, thereby playing a key role in the development of the welfare, teaching and research activities within the Hospital. At the same time, it represents a tool to encourage of multi-hospital cancer research and of cooperation between basic and clinical researchers, constituting important collaboration between biomedical disciplines. The design does not correspond to a Central Tumour Bank, but that of a cooperative and coordinated Network of Hospital Banks, based on simple, homogeneous and optimal tissue treatment protocols. This Network is promoted by the Centro Nacional de Investigaciones Oncologicas (CNIO), which thereby undertakes the work of coordinating the network, using and maintaining the database, adhering to quality control. The aim of the CNIO's TBN is to acquire neoplastic and control non-neoplastic material of all types of malignant neoplasias, in the form of tissue fixed in formalin and paraffin embedded, of samples that are unfixed or frozen according to conventional methods as set out in Annexe 1 and even, exceptionally as fresh tissue. When other types of samples are required to carry out a specific project, the central office of the TBN will draw up a protocol with the group leading the project for the collection and maintenance of the tissue and clinicopathological data required for the proposed research. These protocols will be disseminated among the Associated Hospitals in order to gather the previously agreed number cases. Basic data surrounding the processing and preservation conditions for each case will be sent to the central office of the Bank, which under no circumstances will reveal the identity of the patient. Any Spanish cancer research team will be able to request tissue from the Tissue Bank Network. Absolute priority will be afforded to projects whose principal researcher belongs to one of the Associated Centres of the TNB, to other institutions with special agreements concerning the exchange of samples, and to the CNIO's researchers.clinical, neoplastic tissue, non-neoplastic tissue, tissue, fixed, formalin, paraffin embedded, unfixed, frozen, tumor, cancer, normal controlSCR_008707(Spanish National Tumour Bank Network, RRID:SCR_008707)Spanish National Cancer Research Center Tumor, Cancer, Normal controllisted by: One Mind Biospecimen Bank ListingLast checked downnlx_10273http://www.cnio.es/ing/programas/progTumor01.asp
Cancer Gene IndexResource, data or information resource, databaseTHIS RESOURCE IS NO LONGER SUPPORTED, documented on November 17, 2016. A database of genes that have been experimentally associated with human cancer diseases and/or pharmacological compounds, the evidence of these associations, and relevant annotations on the data.gene, cancer, genetics, pharmacology, disease, database, dataSCR_001117(Cancer Gene Index, RRID:SCR_001117)National Cancer Institute Cancerlisted by: OMICtoolsLast checked upOMICS_01575
Monoclonal Antibody IndexResource, data or information resource, databaseTHIS RESOURCE IS NO LONGER IN SERVICE, documented September 13, 2016. A searchable biotechnology database e-books with information on more than 9000 monoclonal antibodies. This database has antibodies produced for the diagnosis and therapy of human cancer, Alzheimer's disease, AIDS, and other diseases as well as for biomarker and proteomics research. Information such as antibody name, species, type, characteristics, antigen characteristics, and developer or distributor of antibody as well as mentions in journals, patents, abstracts and reports up until 2012 are included.antibody, monoclonal antibody, cancer, aids, sars, heart disease, vascular disease, coagulation disease, transplantation, inflammation, alzheimer's disease, autoimmunity, biomarker, proteomics, resource, research, databaseSCR_013227(Monoclonal Antibody Index, RRID:SCR_013227)listed by: OMICtoolsLast checked upOMICS_01773
X
  1. RRID Portal Resources

    Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.

  2. Navigation

    You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.

  3. Logging in and Registering

    If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.

  4. Searching

    Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:

    1. Use quotes around phrases you want to match exactly
    2. You can manually AND and OR terms to change how we search between words
    3. You can add "-" to terms to make sure no results return with that term in them (ex. Cerebellum -CA1)
    4. You can add "+" to terms to require they be in the data
    5. Using autocomplete specifies which branch of our semantics you with to search and can help refine your search
  5. Collections

    If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.

  6. Facets

    Here are the facets that you can filter the data by.

  7. Further Questions

    If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.